Explore spatial biomarkers in the tissue microenvironment at single-cell resolution with our revolutionary multiplexed imaging solutions.
Location: United States, California, Menlo Park
Employees: 201-500
Total raised: $50M
Founded date: 2015
Investors 3
| Date | Name | Website |
| - | aMoon Fund | amoon.fund... |
| - | Telegraph ... | thpartners... |
| - | StartX | startx.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 05.12.2019 | - | $50M | - |
Mentions in press and media 15
| Date | Title | Description |
| 09.07.2025 | Quanterix Completes Acquisition Of Akoya Biosciences | Quanterix Corporation (NASDAQ: QTRX), a Billerica, MA-based company improving scientific discovery through ultra-sensitive biomarker detection, announced that it has completed its previously announced acquisition of Akoya Biosciences, a Mar... |
| 24.05.2024 | Advancing Spatial Biology to the Clinic: The Power of Multiplex Immunofluorescence-based Biomarkers for Companion Diagnostics, Upcoming Webinar Hosted by Xtalks | www.akoyabio.com In this free webinar, learn about setting up and managing multiplex immunofluorescence (mIF) platforms for companion diagnostics (CDx) and clinical programs. Attendees will discover key technical, regulatory and commercial ... |
| 23.04.2024 | Capitainer Recruits New Sales and Distribution Manager to Strengthen the Sales Organization | Capitainer Recruits New Sales and Distribution Manager to Strengthen the Sales Organization Tue, Apr 23, 2024 07:52 CET Report this content Capitainer, a leading Swedish medtech company that specializes in user-friendly self-sampling soluti... |
| 04.03.2024 | Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook | Q4 2023 revenue $26.5 million and FY 2023 revenue $96.6 million Guiding FY 2024 revenue range $114.0-118.0 million and operating cash flow breakeven by YE 2024 MARLBOROUGH, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (... |
| 08.05.2023 | Akoya Reports Record Revenue in the First Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance | /EIN News/ -- Q1 2023 revenue $21.4 million, 27% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million MARLBOROUGH, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biol... |
| 06.03.2023 | Akoya Reports Record Revenue in the Fourth Quarter of 2022 and Provides Full Year 2023 Revenue Guidance | /EIN News/ -- Q4 2022 revenue $21.2 million and FY 2022 revenue $74.9 million FY 2023 revenue guidance range $95-98 million MARLBOROUGH, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial... |
| 05.01.2022 | Akoya Biosciences and Bio-Techne Partner to Deliver Automated Spatial Multiomics Workflow with Industry-Leading Speed and Resolution | MARLBOROUGH, Mass. and MINNEAPOLIS, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company®, and Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioact... |
| 13.12.2021 | Akoya Biosciences Announces a Groundbreaking Collaboration with PathAI to Combine Spatial Biology with AI-Powered Tools to Facilitate Discovery of Novel Predictive Biomarkers | MARLBOROUGH, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, and PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology, today announced a col... |
| 30.11.2021 | Akoya Biosciences Secures CLIA Lab Certification, a Milestone for Applying Its Spatial Biology Technologies to Accelerating Precision Cancer Therapies | Certification ensures Akoya’s cutting-edge spatial biology tools meet the highest standards for translational medicine and clinical research, with longer term potential for companion diagnostics. MARLBOROUGH, Mass., Nov. 30, 2021 (GLOBE NEW... |
| 01.04.2021 | SITC Announces Two Spatial Technology Awards for Early Career Scientists to Advance Cancer Immunotherapy Research | Society for Immunotherapy of Cancer “SITC views these two unique technology awards as an investment in the future of our field that we hope will lead to innovative and cutting-edge immunotherapy approaches and ultimately better outcomes for... |
Show more